lncRNA FEZF1‑AS1 promotes migration, invasion and epithelial‑mesenchymal transition of retinoblastoma cells by targeting miR‑1236‑3p

Zhang,Guanghong; Yang,Wei; Li,Dujun; Li,Xiaoyu; Huang,Juan; Huang,Rong; Luo,Jihong

doi:10.3892/mmr.2020.11478

lncRNA FEZF1‑AS1 promotes migration, invasion and epithelial‑mesenchymal transition of retinoblastoma cells by targeting miR‑1236‑3p

Authors:
- Guanghong Zhang
- Wei Yang
- Dujun Li
- Xiaoyu Li
- Juan Huang
- Rong Huang
- Jihong Luo
View Affiliations

Affiliations: Department of Ophthalmology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei 430061, P.R. China, Department of Ophthalmology, Hannan District People's Hospital, Wuhan, Hubei 430090, P.R. China, Department of Ophthalmology, Hubei University of Chinese Medicine, Wuhan, Hubei 430065, P.R. China
Published online on: September 2, 2020 https://doi.org/10.3892/mmr.2020.11478
Pages: 3635-3644
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) and microRNAs (miRs) have been reported to regulate disease progression in numerous types of disease, including retinoblastoma (Rb). Therefore, the present study aimed to investigate the effects of the lncRNA FEZ family zinc finger 1 antisense RNA 1 (FEZF1‑AS1) on Rb and to determine its possible mechanism of action. Reverse transcription‑quantitative PCR and western blot analysis were conducted to detect the gene or protein expression. Cell Counting Kit‑8, wound healing and transwell invasion assays were performed to estimate the capabilities of cell viability, invasion and migration. The potential association between FEZF1‑AS1 and miR‑1236‑3p in Y79 cells was measured via dual‑luciferase reporter assay. The results of the present study revealed that the levels of FEZF1‑AS1 were significantly upregulated in different Rb cell lines, with the most prominent upregulation observed in Y79 cells. In addition, the cell viability, invasive and migratory abilities, and the ability to undergo epithelial‑mesenchymal transition (EMT), were significantly inhibited following the transfection of short hairpin RNA (shRNA)‑FEZF1‑AS1 into Y79 cells. Further experimental validation confirmed that miR‑1236‑3p may be a direct target of FEZF1‑AS1. Notably, the miR‑1236‑3p inhibitor was discovered to reverse the inhibitory effects of shRNA‑FEZF1‑AS1 on cell viability, invasion, migration and EMT. In conclusion, the findings of the present study suggested that lncRNA‑FEZF1‑AS1 may promote the viability, migration, invasion and EMT of Rb cells by modulating miR‑1236‑3p.

View Figures

View References

1	Kivelä T: The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
2	Dimaras H and Corson TW: Retinoblastoma, the visible CNS tumor: A review. J Neurosci Res. 97:29–44. 2019. View Article : Google Scholar : PubMed/NCBI
3	Kivelä TT and Hadjistilianou T: Neonatal retinoblastoma. Asia Pac J Oncol Nurs. 4:197–204. 2017. View Article : Google Scholar : PubMed/NCBI
4	Singh L and Kashyap S: Update on pathology of retinoblastoma. Int J Ophthalmol. 11:2011–2016. 2018.PubMed/NCBI
5	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
6	Tiwari N, Gheldof A, Tatari M and Christofori G: EMT as the ultimate survival mechanism of cancer cells. Semin Cancer Biol. 22:194–207. 2012. View Article : Google Scholar : PubMed/NCBI
7	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
8	Kaliki S, Shields CL and Retinoblastoma: Achieving new standards with methods of chemotherapy. Indian J Ophthalmol. 63:103–109. 2015. View Article : Google Scholar : PubMed/NCBI
9	Gao J, Zeng J, Guo B, He W, Chen J, Lu F and Chen D: Clinical presentation and treatment outcome of retinoblastoma in children of south western China. Medicine (Baltimore). 95:e52042016. View Article : Google Scholar : PubMed/NCBI
10	Kim JW, Abramson DH and Dunkel IJ: Current management strategies for intraocular retinoblastoma. Drugs. 67:2173–2185. 2007. View Article : Google Scholar : PubMed/NCBI
11	Rodriguez-Galindo C, Chantada GL, Haik BG and Wilson MW: Treatment of retinoblastoma: Current status and future perspectives. Curr Treat Options Neurol. 9:294–307. 2007. View Article : Google Scholar : PubMed/NCBI
12	Yang M and Wei W: Long non-coding RNAs in retinoblastoma. Pathol Res Pract. 215:1524352019. View Article : Google Scholar : PubMed/NCBI
13	Benavente CA and Dyer MA: Genetics and epigenetics of human retinoblastoma. Annu Rev Pathol. 10:547–562. 2015. View Article : Google Scholar : PubMed/NCBI
14	Xing YH, Bai Z, Liu CX, Hu SB, Ruan M and Chen LL: Research progress of long noncoding RNA in China. IUBMB Life. 68:887–893. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tang JY, Lee JC, Chang YT, Hou MF, Huang HW, Liaw CC and Chang HW: Long noncoding RNAs-related diseases, cancers, and drugs. ScientificWorldJournal. 2013:9435392013. View Article : Google Scholar : PubMed/NCBI
16	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
17	Heery R, Finn SP, Cuffe S and Gray SG: Long non-coding RNAs: Key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 9:382017. View Article : Google Scholar
18	Hao F, Mou Y, Zhang L, Wang S and Yang Y: lncRNA AFAP1-AS1 is a prognostic biomarker and serves as oncogenic role in retinoblastoma. Biosci Rep. 38:BSR201803842018. View Article : Google Scholar : PubMed/NCBI
19	Tamang S, Acharya V, Roy D, Sharma R, Aryaa A, Sharma U, Khandelwal A, Prakash H, Vasquez KM and Jain A: SNHG12: An lncRNA as a potential therapeutic target and biomarker for human cancer. Front Oncol. 9:9012019. View Article : Google Scholar : PubMed/NCBI
20	Shi C, Sun L and Song Y: FEZF1-AS1: A novel vital oncogenic lncRNA in multiple human malignancies. Biosci Rep. 39:BSR201912022019. View Article : Google Scholar : PubMed/NCBI
21	Quan LJ and Wang WJ: FEZF1-AS1 functions as an oncogenic lncRNA in retinoblastoma. Biosci Rep. 39:BSR201907542019. View Article : Google Scholar : PubMed/NCBI
22	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
23	Solé C and Lawrie CH: MicroRNAs and metastasis. Cancers (Basel). 12:962019. View Article : Google Scholar
24	Liu J and Tao C: Overexpression of miRNA-125a-5p inhibits the growth and angiogenesis of hepatocellular carcinoma by regulating the expression of VEGF-A. Biotechnol Biotechnol Equip. 33:1116–1125. 2019. View Article : Google Scholar
25	Bian T, Jiang D, Liu J, Yuan X, Feng J, Li Q, Zhang Q, Li X, Liu Y and Zhang J: miR-1236-3p suppresses the migration and invasion by targeting KLF8 in lung adenocarcinoma A549 cells. Biochem Biophys Res Commun. 492:461–467. 2017. View Article : Google Scholar : PubMed/NCBI
26	Wang Y, Yan S, Liu X, Zhang W, Li Y, Dong R, Zhang Q, Yang Q, Yuan C, Shen K and Kong B: miR-1236-3p represses the cell migration and invasion abilities by targeting ZEB1 in high-grade serous ovarian carcinoma. Oncol Rep. 31:1905–1910. 2014. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Li J, Zhang S, Wu L and Pei M: Interaction between LncRNA-ROR and miR-145 contributes to epithelial-mesenchymal transition of ovarian cancer cells. Gen Physiol Biophys. 38:461–471. 2019. View Article : Google Scholar : PubMed/NCBI
29	Gong J, Wang J, Liu T, Hu J and Zheng J: lncRNA FEZF1-AS1 contributes to cell proliferation, migration and invasion by sponging miR-4443 in hepatocellular carcinoma. Mol Med Rep. 18:5614–5620. 2018.PubMed/NCBI
30	Chi Y, Wang D, Wang J, Yu W and Yang J: Long non-coding RNA in the pathogenesis of cancers. Cells. 8:10152019. View Article : Google Scholar
31	Pelechano V and Steinmetz LM: Gene regulation by antisense transcription. Nat Rev Genet. 14:880–893. 2013. View Article : Google Scholar : PubMed/NCBI
32	Halley P, Kadakkuzha BM, Faghihi MA, Magistri M, Zeier Z, Khorkova O, Coito C, Hsiao J, Lawrence M and Wahlestedt C: Regulation of the apolipoprotein gene cluster by a long noncoding RNA. Cell Rep. 6:222–230. 2014. View Article : Google Scholar : PubMed/NCBI
33	Carrieri C, Cimatti L, Biagioli M, Beugnet A, Zucchelli S, Fedele S, Pesce E, Ferrer I, Collavin L, Santoro C, et al: Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature. 491:454–457. 2012. View Article : Google Scholar : PubMed/NCBI
34	Liu Z, Zhao P, Han Y and Lu S: lncRNA FEZF1-AS1 is associated with prognosis in lung adenocarcinoma and promotes cell proliferation, migration, and invasion. Oncol Res. 27:39–45. 2018. View Article : Google Scholar : PubMed/NCBI
35	Zhang Z, Sun L, Zhang Y, Lu G, Li Y and Wei Z: Long non-coding RNA FEZF1-AS1 promotes breast cancer stemness and tumorigenesis via targeting miR-30a/Nanog axis. J Cell Physiol. 233:8630–8638. 2018. View Article : Google Scholar : PubMed/NCBI
36	Wu X, Zhang P, Zhu H, Li S, Chen X and Shi L: Long noncoding RNA FEZF1-AS1 indicates a poor prognosis of gastric cancer and promotes tumorigenesis via activation of Wnt signaling pathway. Biomed Pharmacother. 96:1103–1108. 2017. View Article : Google Scholar : PubMed/NCBI
37	An JX, Ma MH, Zhang CD, Shao S, Zhou NM and Dai DQ: miR-1236-3p inhibits invasion and metastasis in gastric cancer by targeting MTA2. Cancer Cell Int. 18:662018. View Article : Google Scholar : PubMed/NCBI
38	Wang Z, Liu L, Guo X, Guo C and Wang W: microRNA-1236-3p regulates DDP resistance in lung cancer cells. Open Med (Wars). 14:41–51. 2019. View Article : Google Scholar : PubMed/NCBI
39	Feng W, Gong H, Wang Y, Zhu G, Xue T, Wang Y and Cui G: circIFT80 functions as a ceRNA of miR-1236-3p to promote colorectal cancer progression. Mol Ther Nucleic Acids. 18:375–387. 2019. View Article : Google Scholar : PubMed/NCBI
40	Li C, Ge Q, Liu J, Zhang Q, Wang C, Cui K and Chen Z: Effects of miR-1236-3p and miR-370-5p on activation of p21 in various tumors and its inhibition on the growth of lung cancer cells. Tumour Biol. 39:10104283177108242017. View Article : Google Scholar : PubMed/NCBI